Although co-medication with proton pump inhibitors (PPI) is not advised for patients being treated with dasatanib for their chronic myeloid leukemia (CML), confirmation that this recommendation is often overlooked has been reported in a study led by Torsten Dahlén, a PhD student at the Karolinska Institutet in Stockholm, Sweden.

Furthermore, the study found a higher than previously reported negative interaction of PPI comedication on crystalline dasatinib bioavailability that may compromise clinical efficacy and risk CML disease progression.

The latest findings from the study were reported in a poster session at the 2024 ASCO Annual Meeting where Oncology Times reporter Peter Goodwin met up with Olof Harlin, PhD, of Xspray Pharma, based in Solna, near Stockholm, Sweden.